Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acrux Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Acrux şirketinin toplam hissedar öz sermayesi A$3.3M ve toplam borcu A$1.5M olup, bu da borç-öz sermaye oranını 45.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$9.0M ve A$5.7M dir.

Anahtar bilgiler

45.4%

Borç/özkaynak oranı

AU$1.49m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$2.95m
Eşitlik	AU$3.28m
Toplam yükümlülükler	AU$5.69m
Toplam varlıklar	AU$8.96m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Sep 21

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

May 20

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Feb 04

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Dec 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACR 'nin kısa vadeli varlıkları ( A$6.0M ) kısa vadeli yükümlülüklerini ( A$3.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: ACR şirketinin kısa vadeli varlıkları ( A$6.0M ) uzun vadeli yükümlülüklerini ( A$2.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACR şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ACR şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 45.4% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACR şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 17 oranında tarihsel oranda büyümeye devam ederse ACR un bir yıldan az nakit akışı süresi vardır.

Acrux Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Recent updates

New major risk - Financial position

Full year 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin